|
See related Stocrin tab information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Hong Kong: DKSH/Macau: Four Star |
|
Contents |
Efavirenz |
|
Indications |
Antiviral combination treatment of HIV-1 infected adults, adolescents & childn. |
|
Dosage |
In combination w/ a protease inhibitor &/or nucleoside analogue reverse transcriptase inhibitors Adult & childn ≥40 kg 600 mg once daily. Childn 32.5 to <40 kg 400 mg. To be taken once daily. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Hypersensitivity. Concomitant terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bedipril, or ergot derivatives & standard doses of voriconazole & w/ combination products that contain efavirenz. |
|
Special Precautions |
Must be given in combination w/ other antiretroviral medications. Potential for viral cross-resistance. Pregnancy. Lactation. Liver disease & renal impairment. Monitor liver enzymes in hepatitis B or C infection & in patients treated w/ other medications associated w/ liver toxicity. |
|
Adverse Drug Reactions |
Rash, nausea, dizziness, diarrhea, headache, insomnia, fatigue & impaired conc. Somnolence, abnormal dreaming, depression, abnormal thinking, agitation, amnesia, delirium, emotion liability, euphoria, hallucination & psychosis.
View ADR Monitoring Form |
|
Drug Interactions |
CYP3A4 inducer. Atazanavir, indinavir, ritonavir, saquinavir; maraviroc & posaconazole; itraconazole & posaconazole; rifampin, clarithromycin, atorvastatin, pravastatin or simvastatin. Methadone, St. John's wort, sertraline, Ca-channel blockers, carbamazepine.
View more drug interactions with Stocrin |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
